• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

PLoS Pathogens. Evidence for Antigenic Seniority in Influenza A (H3N2) Antibody Responses in Southern China

Giuseppe

Emeritus
[Source: PLoS Pathogens, full text: (LINK). Abstract, edited.]

Evidence for Antigenic Seniority in Influenza A (H3N2) Antibody Responses in Southern China



Justin Lessler<SUP>1</SUP>, Steven Riley<SUP>2</SUP><SUP>*</SUP>, Jonathan M. Read<SUP>3</SUP>, Shuying Wang<SUP>4</SUP>, Huachen Zhu<SUP>5</SUP><SUP>,</SUP><SUP>6</SUP>, Gavin J. D. Smith<SUP>7</SUP>, Yi Guan<SUP>5</SUP><SUP>,</SUP><SUP>6</SUP>, Chao Qiang Jiang<SUP>4</SUP>, Derek A. T. Cummings<SUP>1</SUP>

1 Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America, 2 School of Public Health, Department of Infectious Disease Epidemiology, MRC Centre for Outbreak Analysis and Modelling, Imperial College, London, United Kingdom, 3 Department of Epidemiology and Population Health, Institute of Infection and Global Health, Faculty of Health and Life Sciences, University of Liverpool, Liverpool, United Kingdom, 4 Guangzhou No. 12 Hospital, Guangzhou, Guangdong, China, 5 International Institute of Infection and Immunity, Shantou University Medical College, Shantou, Guangdong, China, 6 Department of Microbiology, The University of Hong Kong, Hong Kong SAR, China, 7 Laboratory of Virus Evolution, Program in Emerging Infectious Diseases, Duke-NUS Graduate Medical School, Singapore, Singapore



Abstract

A key observation about the human immune response to repeated exposure to influenza A is that the first strain infecting an individual apparently produces the strongest adaptive immune response. Although antibody titers measure that response, the interpretation of titers to multiple strains ? from the same sera ? in terms of infection history is clouded by age effects, cross reactivity and immune waning. From July to September 2009, we collected serum samples from 151 residents of Guangdong Province, China, 7 to 81 years of age. Neutralization tests were performed against strains representing six antigenic clusters of H3N2 influenza circulating between 1968 and 2008, and three recent locally circulating strains. Patterns of neutralization titers were compared based on age at time of testing and age at time of the first isolation of each virus. Neutralization titers were highest for H3N2 strains that circulated in an individual's first decade of life (peaking at 7 years). Further, across strains and ages at testing, statistical models strongly supported a pattern of titers declining smoothly with age at the time a strain was first isolated. Those born 10 or more years after a strain emerged generally had undetectable neutralization titers to that strain (<1:10). Among those over 60 at time of testing, titers tended to increase with age. The observed pattern in H3N2 neutralization titers can be characterized as one of antigenic seniority: repeated exposure and the immune response combine to produce antibody titers that are higher to more ?senior? strains encountered earlier in life.



Author Summary

The human immune response to an influenza infection is not the same for every infection. It has often been observed that we tend to have the highest antibody titer (and presumably our strongest immune response) against strains of influenza that we were exposed to early in life. In this study, we obtained blood samples from 151 people between 7 and 81 years of age and tested the samples for the concentration of antibodies to many different (H3N2) strains. We chose strains according to when they first circulated, starting with a strain isolated just after the 1968 pandemic and going all the way through to very recent strains. We found that a participant's age at the time a strain first circulated was very predictive of the strength of their antibody against that strain. Not just for the first strain they were likely to have seen, but also for the second, third and all subsequent strains circulating during their lifetime. This suggests to us that antibody titers to influenza A H3N2 follow a pattern of antigenic seniority, suggesting that we produce progressively fewer specific antibodies to each subsequent infection as we age.


Citation: Lessler J, Riley S, Read JM, Wang S, Zhu H, et al. (2012) Evidence for Antigenic Seniority in Influenza A (H3N2) Antibody Responses in Southern China. PLoS Pathog 8(7): e1002802. doi:10.1371/journal.ppat.1002802

Editor: Christopher F. Basler, Mount Sinai School of Medicine, United States of America

Received: September 11, 2011; Accepted: June 1, 2012; Published: July 19, 2012

Copyright: ? 2012 Lessler et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This study was supported by: a grant from the National Institutes of Health Fogarty Institute (1 R01 TW 0008246-01); the RAPIDD program from Fogarty International Centre with the Science & Technology Directorate, Department of Homeland Security (SR, DATC); Career Award at the Scientific Interface from the Burroughs Wellcome Fund (DATC); and Wellcome Trust University Award 093488/Z/10/Z (SR). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing interests: The authors have declared that no competing interests exist.

* E-mail: s.riley@imperial.ac.uk
- -------
 
Back
Top Bottom